Entresto reduces risk of cardiovascular death

Entresto (sacubitril-valsartan) from Novartis is FDA indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure.

Entresto remains the only FDA-approved option for patients with a variety of heart failure symptoms. A recent pilot study shows that the drug may also benefit patients with heart failure with reduced ejection fraction (HFrEF), according to AJMC.

Read more
  • 0